medigraphic.com
Academia Mexicana de Neurología, A.C.

2016, Number 6

Next >>

Rev Mex Neuroci 2016; 17 (6)

Multiple sclerosis: current situation and future trends

Fernández O, Cuevas C, Arcega R, Núñez-Orozco L, Carrasco-Vargas H, Ordoñez-Boschetti L, De La Maza JM, Sauri-Suárez S, Arrambide G, Padilla O, Blaisdel C, Quiñones S, Carrera R

Language: Spanish
References: 43
Page: 3-22
PDF size: 307.67 Kb.


ABSTRACT

In this article it is described the proposals on various aspects of current interest in multiple sclerosis, which were derived from a scientific meeting with Mexican specialists in 2013 and based on a detailed review of the literature by working groups and plenary discussion. This article intents to provide answer to clinical questions relating with the criteria for deciding the observational monitoring and clinical follow-up, medical treatment of clinically isolated syndrome, a rational treatment initiation of relapsing-remitting multiple sclerosis, clinical criteria to evaluate the evolution of relapsing-remitting multiple sclerosis, therapeutic failure and the criteria for step-bystep treatment.


REFERENCES

  1. Carra A, Macias-Islas MA, Gabbai AA, Correale J, Bolana C, Sotelo ED, et al. Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America. Ther Adv Neurol Disord 2011; 4: 349-360.

  2. Henze T, Rieckmann P, Toyka KV, Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol 2006; 56: 78-105.

  3. Garcia-Merino A, Fernandez O, Montalban X, de Andres C, Oreja-Guevara C, Rodriguez-Antiguedad A, et al. Consensus Statement on medication use in multiple sclerosis by the Spanish Society of Neurology’s study group for demyelinating diseases. Neurologia 2013; 28: 375-378.

  4. Bohlega S, Inshasi J, Al Tahan AR, Madani AB, Qahtani H, Rieckmann P. Multiple sclerosis in the Arabian Gulf countries: a consensus statement. J Neurol 2013; 260: 2959-2963.

  5. Yamout B, Alroughani R, Al-Jumah M, Khoury S, Abouzeid N, Dahdaleh M, et al. Consensus guidelines for the diagnosis and treatment of multiple sclerosis. Curr Med Res Opin 2013; 29: 611- 621.

  6. Yamout B, El-Salem K, Gebeily S, Khoury S, Abu Zeid N, Hamoulila K, et al. Multiple sclerosis in the Levant: a regional consensus statement. Int J Neurosci 2013; 124: 377-382

  7. Miller RM, Happe LE, Meyer KL, Spear RJ. Approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of U.S. managed care pharmacists and physicians. J Manag Care Pharm 2012; 18: 54-62.

  8. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.

  9. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.

  10. Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 1489-1496.

  11. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898-904.

  12. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370: 389-897.

  13. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1503- 1511.

  14. Patrucco L, Rojas JI, Miguez JS, Cristiano E. Application of the McDonald 2010 criteria for the diagnosis of multiple sclerosis in an Argentinean cohort of patients with clinically isolated syndromes. Mult Scler 2013; 19: 1297-1301.

  15. Swanton JK, Fernando K, Dalton CM, Miszkiel KA, Thompson AJ, Plant GT, et al. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2006; 77: 830-833.

  16. Geurts JJ, Roosendaal SD, Calabrese M, Ciccarelli O, Agosta F, Chard DT, et al. Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology 2011; 76: 418-424.

  17. Pelayo R, Montalban X, Minoves T, Moncho D, Rio J, Nos C, et al. Do multimodal evoked potentials add information to MRI in clinically isolated syndromes? Mult Scler 2010; 16: 55-61.

  18. Butzkueven H, KapposL,PellegriniF, et al. J Neurol Neurosur Psychiatry 2014; 85: 1190-1197.

  19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.

  20. Whitaker JN, Mitchell GW, Cutter GR. Clinical outcomes and documentation of partial beneficial effects of immunotherapy for multiple sclerosis. Ann Neurol 1995; 37: 5-6.

  21. Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, et al. Clinical outcomes assessment in multiple sclerosis. Ann Neurol 1996; 40: 469-479.

  22. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-882.

  23. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-1151.

  24. Ashworth B. Preliminary Trial of Carisoprodol in Multiple Sclerosis. Practitioner 1964; 192: 540- 542.

  25. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67: 206-207.

  26. Vickrey BG, Hays RD, Genovese BJ, Myers LW, Ellison GW. Comparison of a generic to diseasetargeted health-related quality-of-life measures for multiple sclerosis. J Clin Epidemiol 1997; 50: 557-569.

  27. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995; 4: 187-206.

  28. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991; 41: 685-691.

  29. Rieckmann P, Toyka KV. Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG. Eur Neurol 1999; 42: 121-127.

  30. O’Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005; 11: 46-50.

  31. Gauthier SA, Glanz BI, Mandel M, Tsagkaropoulos A, Neema M, Stankiewicz J, et al. Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study. J Neurol Sci 2009; 284: 116-119.

  32. Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M, et al. Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations. Can J Neurol Sci 2013; 40: 307-323.

  33. Kantarci OH, Weinshenker BG. Prognostic Factors in Multiple Sclerosis. In: Cook S, editor. Handbook of Multiple Sclerosis. 3 ed. ed. New York: Marcel Dekker; 2001, p. 449-463.

  34. Garcia Merino A, Fernandez O, Montalban X, de Andres C, Arbizu T. Spanish Neurology Society consensus document on the use of drugs in multiple sclerosis: escalating therapy. Neurologia 2010; 25: 378-390.

  35. Karussis D, Biermann LD, Bohlega S, Boiko A, Chofflon M, Fazekas F, et al. A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. Eur J Neurol 2006; 13: 61-71.

  36. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BG, Burks JS. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996; 46: 12-18.

  37. Abad P, Nogales-Gaete J, Rivera V, Cristiano E, Hamuy F, Oehninger C, et al. LACTRIMS consensus document for the pharmacological treatment of the multiple sclerosis and its clinical variants. Rev Neurol 2012; 55: 737-748.

  38. Rio J, Nos C, Tintore M, Borras C, Galan I, Comabella M, et al. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 2002; 52: 400-406.

  39. Carra A, Onaha P, Luetic G, Burgos M, Crespo E, Deri N, et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. Eur J Neurol 2008; 15: 386-393.

  40. Rio J, Castillo J, Rovira A, Tintore M, Sastre-Garriga J, Horga A, et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009; 15: 848-853.

  41. Rieckmann P. Concepts of induction and escalation therapy in multiple sclerosis. J Neurol Sci 2009; 277: S42-5.

  42. Finkelsztejn A, Gabbai AA, Fragoso YD, Carra A, Macias-Islas MA, Arcega-Revilla R, et al. Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents. Arq Neuropsiquiatr 2012; 70: 799-806.

  43. Rio J, Comabella M, Montalban X. Multiple sclerosis: current treatment algorithms. Curr Opin Neurol 2011; 24: 230-237.




2020     |     www.medigraphic.com